tm logo
SURMOUNT BIO
SEARCHED

on 10 Jun 2024

Last Applicant/ Owned by

ELEVATEBIO LLC

One Main StreetCambridge, MA 01242

US

Serial Number

1979064 filed on 05th Aug 2019

Correspondent Address

SUITE 1000, 55 METCALFE STREETP.O. BOX 2999, STATION DOttawa

ONTARIO

CA

K1P5Y6

SURMOUNT BIO

Trademark usage description

gene therapy products, namely, genetically engineered tissues for transplant purposes; pharmaceutical preparations and substances for the treatment of Read More

Classification Information


Class [005]
Gene therapy products, namely, genetically engineered tissues for transplant purposes; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, antivirals; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Anti-cancer preparations; Biological preparations for the treatment of cancer; Digestives for pharmaceutical purposes; Drug delivery agents in the form of a capsule, pill, or other digestible that facilitate the delivery of pharmaceutical preparations; Medical preparations for the treatment of Cancer and Acute and Chronic Devastating Diseases and Conditions beyond Cancer; Medicinal infusions for treating Cancer and Acute and Chronic Devastating Diseases and Conditions beyond Cancer; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicinal preparations for the treatment of cancer and Acute and Chronic Devastating Diseases and Conditions beyond Cancer; Mixed biological preparations for the prevention and treatment of infectious diseases; Pharmaceutical preparations for the treatment and prevention of Cancer and Acute and Chronic Devastating Diseases and Conditions beyond Cancer; Pharmaceutical preparations for the treatment of Cancer and Acute and Chronic Devastating Diseases and Conditions beyond Cancer; Pharmaceutical preparations for the treatment of Cancer and Acute and Chronic Devastating Diseases and Conditions beyond Cancer; Pharmaceutical products for the prevention and treatment of cancer; Radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; Specialized tablets, capsules and powders for the delivery of pharmaceuticals sold without the pharmaceutical ingredient; Therapeutic pharmaceutical for the treatment of Cancer and Acute and Chronic Devastating Diseases and Conditions beyond Cancer; Unit dose capsules sold empty for pharmaceutical use.


Classification kind code

11

Class [042]
Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Research and development of vaccines and medicines; Research and development services in the field of antibodies; Biochemical research and development; Conducting clinical trials for others; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Medical and scientific research in the field of cancer treatment and diagnosis; Medical and scientific research, namely, conducting clinical trials for others; Medical research services in the field of cancer; Pharmaceutical research and development; Providing a web site featuring technology enabling physicians to access resources in clinical medicine; Providing a website featuring educational information in the field of clinical research; Providing laboratory research services in the field of gene expression, namely, cancer biology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Providing medical testing services and information in the field of cancer research and disease classification; Scientific research and development; Scientific and technological services, namely, research and design in the field of integrated system architecture that allows for the rapid development of highly interactive and customizable learning applications; Scientific research for medical purposes in the area of cancerous diseases; Scientific research for medical purposes in the field of Cancer and Acute and Chronic Devastating Diseases and Conditions beyond Cancer; Stem cell research services; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy.


Classification kind code

11

Mark Details


Serial Number

1979064

Mark Type

Trademark

Legal History


Action TakenStatus
Submitted for opposition 22
on 10th Jun 2024
Search Recorded
Submitted for opposition 20
on 10th Jun 2024
Examiner's First Report
Submitted for opposition 67
on 29th Sep 2023
Agent Name Changed
Submitted for opposition 287
on 10th May 2022
Pre-Assessment Letter Sent
Submitted for opposition 48
on 02th Nov 2021
Agent Changed
Submitted for opposition 31
on 08th Aug 2019
Formalized
Submitted for opposition 1
on 06th Aug 2019
Created
Submitted for opposition 30
on 05th Aug 2019
Filed